Tumor News and Research

RSS
Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Personalized vaccine processed using tumor tissue promising for brain tumor treatment

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Approval of personalized therapy for lung cancer in Europe will change way of treatment

Approval of personalized therapy for lung cancer in Europe will change way of treatment

Researchers explore role of ECoG measurement to improve brain mapping technology

Researchers explore role of ECoG measurement to improve brain mapping technology

New study shows people with BAV more likely to have brain aneurysms

New study shows people with BAV more likely to have brain aneurysms

Novel combined immunotherapy promising for treatment of malignant brain tumors

Novel combined immunotherapy promising for treatment of malignant brain tumors

BioMarker Strategies receives $1M NCI grant funding to develop SnapPath live tumor cell testing system

BioMarker Strategies receives $1M NCI grant funding to develop SnapPath live tumor cell testing system

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

Researchers evaluate efficacy of GKRS in patients with pituitary adenoma

Broccoli component sulforaphane targets and kills breast cancer stem cells

Broccoli component sulforaphane targets and kills breast cancer stem cells

NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in Hispanic women

NIH awards Hutchinson Center $10.24M for research of breast cancer disparities in Hispanic women

QIAGEN reports 20% revenue growth in first quarter 2010

QIAGEN reports 20% revenue growth in first quarter 2010

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Protein test to determine response of lung cancer patients to erlotinib

Protein test to determine response of lung cancer patients to erlotinib

ExacTrac SV system allows precise targeting of radiotherapy using real-time X-ray images

ExacTrac SV system allows precise targeting of radiotherapy using real-time X-ray images

Promising results from combination therapy of pemetrexed concurrent with radiation in lung cancer

Promising results from combination therapy of pemetrexed concurrent with radiation in lung cancer

BSGI improves breast cancer detection

BSGI improves breast cancer detection

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

FDA oks 'vaccine' to treat prostate cancer

FDA oks 'vaccine' to treat prostate cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.